Clinical trial NCT06734468: Personalized Approach to Promote Healthy Aging
Official title: Personalized Approach to Promote Healthy Aging
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Aging
Aging, Healthy
Keywords: Healthy aging
Aging
Healthspan
Lead sponsor: Arizona State University
Sponsor class: OTHER
First posted: 2024-12-16
Enrollment: 25
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A pre-post design will be used, with all participants receiving the intervention.
Primary purpose: PREVENTION

Brief summary: The goal of this clinical trial study is to evaluate the impact of a personalized lifestyle intervention on improving healthspan. The primary questions of interest are whether the personalized intervention will result in improvements in muscle function, immune function, and cognitive function in adults aged 50-85 years. Participants will complete baseline assessments, receive an individualized intervention plan for approximately 3 months, and then complete post-intervention assessments. The intervention includes an exercise plan, nutrition recommendations, and general lifestyle goals that will be personalized to each participant.


Eligibility criteria: Inclusion Criteria:

* 50-85 years of age
* Non-smoking
* Ambulatory without the need of an assistive device (walker, cane, etc.) and able to perform exercise testing and exercise training
* English speaking
* Owns a smart phone

Exclusion Criteria:

* Minors and adults younger than age 50 years and older than 85 years
* Pregnant women
* Adults who are unable to provide informed consent
* Prisoners

Primary outcomes:
measure: VO2 max
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Biodex
timeFrame: From baseline to the end of the intervention at 3 months.
Secondary outcomes:
measure: World Health Organization Quality of Life Survey
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Pittsburgh Sleep Quality Index
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Handgrip strength
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Dual Energy X-ray Absorptiometry (DXA)
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Waist circumference
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Hip circumference
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Systolic blood pressure
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Diastolic blood pressure
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Digit Symbol Substitution Test (DSST)
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Montreal Cognitive Assessment (MoCA)
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Short Physical Performance Battery
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Low Density Lipoprotein Cholesterol
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Hemoglobin A1C Concentration
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Insulin Concentration
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Geriatric Depression Scale (GDS)
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Generalized Anxiety Disorder (GAD)-7
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Perceived Stress Scale
timeFrame: From baseline to the end of the intervention at 3 months.
measure: High Density Lipoprotein Cholesterol
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Brief Resilience Scale
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Non-High Density Lipoprotein Cholesterol
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Very Low Density Lipoprotein Cholesterol
timeFrame: From baseline to the end of the intervention at 3 months.
measure: CD3 T cells
timeFrame: From baseline to the end of the intervention at 3 months.
measure: CD4 T cells
timeFrame: From baseline to the end of the intervention at 3 months.
measure: CD8 T cells
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Natural Killer cells
timeFrame: From baseline to the end of the intervention at 3 months.
measure: B cells
timeFrame: From baseline to the end of the intervention at 3 months.
Other outcomes:
measure: Resting metabolic rate
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Red Blood Cells
timeFrame: From baseline to the end of the intervention at 3 months.
measure: White blood cells
timeFrame: From baseline to the end of the intervention at 3 months.
measure: Platelets
timeFrame: From baseline to the end of the intervention at 3 months.
Locations:
city: Phoenix
country: United States
facility: Wexford Innovation Center
state: Arizona
city: Phoenix
country: United States
facility: Wexford Innovation Center
state: Arizona
Study officials:
References: